Literature DB >> 8539320

Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects.

C Smadja1, R Maldonado, S Turcaud, M C Fournie-Zaluski, B P Roques.   

Abstract

Systemic administration of RB 101, a complete inhibitor of the enkephalin degrading enzymes, has been reported to induce naltrindole-reversed antidepressant-like effects in the conditioned suppression of motility (CSM) test in mice. The selective CCKB antagonist L-365,260 also elicits the same naltrindole-blocked responses on CSM. The aim of this study was therefore to investigate the possible modulation of RB 101 induced behavioral responses by activation or blockade of CCK receptors. Thus, the effects induced by RB 101 administered alone or associated with an ineffective dose of a selective CCKB agonist (BC 264), a CCKB antagonist (L-365,260) or a CCKA antagonist (L-364,718), were evaluated on the CSM in mice. RB 101 alone decreased the stress-induced loss of motility, as previously reported. The antidepressant-like effect of RB 101 was potentiated by L-365,260, and suppressed by BC 264 and to a lesser extent by L-364,718. The facilitatory effect induced by L-365,260 on RB 101 responses was blocked by the delta selective antagonist naltrindole. All these effects occurred only in shocked animals. The present results suggest that the activation of CCKA and CCKB receptors by endogenous CCK, could play an opposite role in the control of behavioral responses induced by endogenous enkephalins. Delta opioid receptors seem to be selectively involved in this interaction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8539320     DOI: 10.1007/bf02245811

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  54 in total

1.  Differential inhibitory/stimulatory modulation of spinal CCK release by mu and delta opioid agonists, and selective blockade of mu-dependent inhibition by kappa receptor stimulation.

Authors:  J J Benoliel; S Bourgoin; A Mauborgne; J C Legrand; M Hamon; F Cesselin
Journal:  Neurosci Lett       Date:  1991-04-01       Impact factor: 3.046

Review 2.  Animal models of depression: an overview.

Authors:  P Willner
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Chronic blockade of D2 but not D1 dopamine receptors facilitates behavioural responses to endogenous enkephalins, protected by kelatorphan, administered in the accumbens in rats.

Authors:  R Maldonado; V Daugé; J Feger; B P Roques
Journal:  Neuropharmacology       Date:  1990-03       Impact factor: 5.250

4.  Brain CCK receptors are structurally distinct from pancreas CCK receptors.

Authors:  C Sakamoto; J A Williams; I D Goldfine
Journal:  Biochem Biophys Res Commun       Date:  1984-10-30       Impact factor: 3.575

5.  Two brain cholecystokinin receptors: implications for behavioral actions.

Authors:  T H Moran; P H Robinson; M S Goldrich; P R McHugh
Journal:  Brain Res       Date:  1986-01-01       Impact factor: 3.252

6.  Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.

Authors:  F Noble; J M Soleilhac; E Soroca-Lucas; S Turcaud; M C Fournie-Zaluski; B P Roques
Journal:  J Pharmacol Exp Ther       Date:  1992-04       Impact factor: 4.030

7.  Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.

Authors:  O Valverde; R Maldonado; M C Fournie-Zaluski; B P Roques
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

8.  Stimulation of delta-opioid receptors reduces the in vivo binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins.

Authors:  M Ruiz-Gayo; C Durieux; M C Fournié-Zaluski; B P Roques
Journal:  J Neurochem       Date:  1992-11       Impact factor: 5.372

9.  Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists.

Authors:  F Noble; C Smadja; B P Roques
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

10.  Inhibition of enkephalin degradation attenuated stress-induced motor suppression (conditioned suppression of motility).

Authors:  T Nabeshima; A Katoh; T Kameyama
Journal:  J Pharmacol Exp Ther       Date:  1988-01       Impact factor: 4.030

View more
  5 in total

1.  The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats.

Authors:  O Valverde; M C Fournie-Zaluski; B P Roques; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

2.  Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system.

Authors:  Blandine Pommier; Françoise Beslot; Axelle Simon; Matthieu Pophillat; Toshimitsu Matsui; Valérie Dauge; Bernard P Roques; Florence Noble
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

3.  Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism.

Authors:  F Ruiz; M C Fournié-Zaluski; B P Roques; R Maldonado
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 4.  Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction.

Authors:  B P Roques; F Noble
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

5.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.